Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (223)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (636)
  2. Solid Tumor Oncology Division (636)
  3. Thoracic Oncology (636)
  4. Department of Pathology and Laboratory Medicine (208)
  5. GSK Faculty (189)
  6. Human Oncology and Pathogenesis Program (158)

More Groups

People
  1. Marc Ladanyi (122)
  2. Mark Kris (90)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (20)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (636)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intra-individueller vergleich aus studien mit larotrectinib bei TRK-fusionstumoren – Ein erweiterter datensatz
    Meeting Abstract

    Leyvraz, S.; Italiano, A.; Drilon, A.; Shen, L.; van Tilburg, C. M.; Lin, J. J.; Kummar, S.; Doz, F.; Geoerger, B.; Briggs, A.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Langzeit-wirksamkeit und -sicherheit von larotrectinib in einer gepoolten analyse von patienten mit tropomyosin-rezeptor-kinase (TKR)-fusionstumoren
    Meeting Abstract

    Leyvraz, S.; Drilon, A.; van Tilburg, C. M.; Doz, F.; Kummar, S.; Lin, J. J.; McDermott, R.; Norenberg, R.; Fellous, M.; Brega, N.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Tumor agnostic efficacy of selpercatinib in patients with RET fusion plus solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001)
    Meeting Abstract

    Subbiah, V.; Wolf, J.; Konda, B.; Kang, H.; Spira, A. I.; Weiss, J.; Takeda, M.; Ohe, Y.; Khan, S. A.; Ohashi, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The development of APS03118, a potent next-generation RET inhibitor for treating RET-inhibitor-resistant patients
    Meeting Abstract

    Subbiah, V.; Zhong, J.; Lu, Y.; Liu, Y.; Chen, M.; Chen, X.; Wang, H.; Zhu, J.; Lu, S.; Drilon, A. E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic and mutational landscape of BRAF(V600E)-mutant non-small cell lung carcinoma
    Meeting Abstract

    Sui, J. S. Y.; Ladanyi, M.; Rudin, C. M.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Offin, M.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
    Meeting Abstract

    Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC
    Meeting Abstract

    Rajaram, R.; Sholl, L. M.; Dacic, S.; Goldman, J. W.; Tan, D. S. W.; Gautschi, O.; Loong, H. H. F.; De Braud, F. G.; Massarelli, E.; Levy, B. P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress)
    Meeting Abstract

    Pennell, N. A.; Wirth, L. J.; Gainor, J. F.; Rotow, J. K.; Johnson, M. L.; Bauer, T. M.; Kroiss, M.; Sukrithan, V.; Kang, H.; Worden, F. P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors
    Meeting Abstract

    Perreault, S.; Drilon, A. E.; Lassen, U. N.; Geoerger, B.; Nysom, K.; Øra, I.; Gavrilovic, I. T.; Norenberg, R.; Fellous, M. M.; De la Cuesta, E. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib
    Meeting Abstract

    Murciano-Goroff, Y. R.; Falcon, C. J.; Lin, S. T.; Dhawan, A.; Grimaldi, G.; Liu, D.; Wilhelm, C.; Thomas, R.; Iasonos, A.; Drilon, A. E.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save